Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Socazolimab in Recurrent or Metastatic Cervical Cancer
NCT03676959Phase 1Unknown
- Sponsor
- Lee's Pharmaceutical Holdings Limited
- Start
- Aug 2018
- Primary completion
- May 2022
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label trial of socazolimab in Cervical Cancer (CC) (3 arms), sponsored by Lee's Pharmaceutical Holdings Limited. Primary endpoints: Recommended Phase 2 Dose at 28 days, Objective Response Rate at 2 years and 1 more. Status: unknown.
02
Drugs
socazolimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT03676959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03676959.